The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer.
Tiffany P. Avery
No relevant relationships to disclose
Adam C. Berger
No relevant relationships to disclose
Albert J. Kovatich
No relevant relationships to disclose
Hallgeir Rui
No relevant relationships to disclose
Terry Hyslop
No relevant relationships to disclose
Edith P. Mitchell
No relevant relationships to disclose